Free Newsletter
Drug-suicide link complex, data elusive
Is it possible to draw a straight line between patient suicide and prescription drugs? It's a touchy subject. Within the last few weeks, the FDA alerted the public that epilepsy drugs appear to boost the remote risk of suicide (or at least suicidal thoughts), that Pfizer's stop-smoking drug Chantix may do the same, and that it's requiring more suicide-related data in drug trials. Is suicide the scary drug risk du jour? Or is the explosion activity long overdue?
The New York Times examines the question today and basically concludes that clarity will be elusive. Unless, that is, lawmakers mandate massive databases of patient-and-drug info designed to sift out rare side effects.
- check out the NYT's release
Related Articles:
FDA: Chantix may pose psych risks. Report
FDA gets 5,000 Chantix complaints. Report
'Erratic' behavior triggers Chantix probe. Report
FDA: Epilepsy drugs boost suicidal thoughts. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: